Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Positive impact of high-throughput drug sensitivity assay and salvage autologous CD19 CAR-T therapy on second marrow relapse of acute lymphoblastic leukemia with NT5C2 mutation
  • +10
  • Xue Tang,
  • Lijiao Qin,
  • Lulu Wang,
  • Cheng Jiao,
  • Fen Chen,
  • Yuchen Liu,
  • Guichi Zhou,
  • Sixi Liu,
  • Ying Wang,
  • Shilin Liu,
  • Feiqiu Wen,
  • Lung-Ji Chang,
  • Huirong Mai
Xue Tang
Shenzhen Children's Hospital
Author Profile
Lijiao Qin
Shenzhen Children's Hospital
Author Profile
Lulu Wang
Shenzhen Children's Hospital
Author Profile
Cheng Jiao
Shenzhen Geno-immune Medical Institute
Author Profile
Fen Chen
Shenzhen Children's Hospital
Author Profile
Yuchen Liu
Shenzhen Geno-immune Medical Institute
Author Profile
Guichi Zhou
Shenzhen Children's Hospital
Author Profile
Sixi Liu
Shenzhen Children's Hospital
Author Profile
Ying Wang
Shenzhen Children's Hospital
Author Profile
Shilin Liu
Shenzhen Children's Hospital
Author Profile
Feiqiu Wen
Shenzhen Children's Hospital
Author Profile
Lung-Ji Chang
Shenzhen Geno-immune Medical Institute
Author Profile
Huirong Mai
Shenzhen Children's Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Background: A 12-year-old girl diagnosed with intermediate risk B-ALL in 2017 received chemotherapy according to CCLG-2008 ALL protocol and achieved a complete remission (CR) after induction. However, four years later, she had a first bone marrow relapse and received treatment with HKPHOSG Relapsed ALL 2007 protocol. During maintenance chemotherapy, approximately one year after the first relapse, she developed a second bone marrow relapse with NT5C2 gene mutation detected. Tumor burden was not well controlled after DEAV chemotherapy, with the blasts in bone marrow increasing from 49.3% to 96%. The analysis of high-throughput drug sensitivity of tumor resistant genes was consistent with the poor response to chemotherapy. Procedure: CAR-T cell immunotherapy bridged to HSCT was introduced at this stage. Following peripheral lymphocyte apheresis, the patient received lymphodepleting conditioning with fludarabine and cyclophosphamide three days before CAR-T cell infusion. Dexamethasone and carfilzomib were then given according to the outcome of high-throughput drug sensitivity test. Result: Around 68.6% blasts were detected by flow cytometry at the day of CAR-T cell infusion. The patient experienced grade 1 CRS without ICANS. CR of morphology and molecule biology was achieved on day 28 after CAR-T cell infusion. Finally the child received haploid-HSCT and remained in remission. Conclusion: Overall, this report reveals that the combination of drug sensitivity test with lymphodepleting conditioning could significantly reduce the tumor burden before infusion of CART cells, and patients may achieve deeper remission and obtain opportunity for transplantation.